Published: Jun 26, 2026
Written by Klarity Editorial Team
Published: Jun 26, 2026

If you’re a psychiatrist or PMHNP navigating the world of telehealth prescribing, you already know the regulations can feel like a minefield. One state lets you prescribe stimulants via video on day one. Another requires a physician co-sign, monthly meetings, and a stack of paperwork before you can write for anything stronger than an SSRI.
The good news? Telehealth prescribing in psychiatry is more accessible now than ever, thanks to federal waivers and state-level reforms. The confusing part? Those rules vary wildly depending on where your patient is sitting when you hit ‘send’ on that e-prescription.
Let’s cut through the noise and talk about what you can actually prescribe as a psychiatric provider in 2026 — and what hoops you’ll need to jump through depending on your credentials and your state.
If you’re a psychiatrist (MD/DO), you have the broadest prescribing authority in mental health. In all 50 states, you can prescribe any psychiatric medication independently — antidepressants, antipsychotics, mood stabilizers, stimulants, benzodiazepines, buprenorphine, you name it.
The only real question is whether you can do it via telehealth and whether you need an initial in-person visit for controlled substances.
Historically, the Ryan Haight Act required an in-person medical evaluation before prescribing Schedule II–V controlled substances. For psychiatry, that meant you couldn’t start someone on Adderall, Klonopin, or Suboxone over a video call.
Then COVID happened.
Since March 2020, the DEA has waived that in-person requirement under a public health emergency flexibility. That waiver has been extended multiple times and remains in effect through December 31, 2025. In practice, this means:
What happens after 2025? The DEA has proposed permanent rules that would allow some telehealth prescribing of controlled substances with conditions — like a 30-day supply limit for initial prescriptions or requiring an in-person visit within a certain timeframe. But as of early 2026, those rules are still in draft form. Most experts expect the DEA to extend the current flexibilities again or implement a more lenient final rule, given the overwhelming demand for tele-mental health services.
Bottom line for psychiatrists: You can manage ADHD, anxiety disorders, and opioid use disorder entirely online right now. Just stay tuned for DEA updates and be prepared to pivot if the rules tighten.
While federal law sets the floor, state laws add extra requirements — and some are more telehealth-friendly than others.
Some states have gone out of their way to make this easy for psychiatrists:
Florida: Florida law explicitly permits prescribing controlled substances via telehealth for psychiatric treatment. The statute carves out mental health as an exception to their general prohibition on tele-prescribing controlled drugs for chronic pain management. If you’re treating a Florida patient for depression, ADHD, or anxiety, you can prescribe psychotropics remotely without issue.
Texas: Texas allows telemedicine prescribing if the standard of care is met and the encounter involves real-time audio-visual interaction. The state prohibits tele-prescribing opioids for chronic pain but doesn’t restrict prescribing stimulants or benzodiazepines for psychiatric conditions. You can manage ADHD or anxiety via telehealth in Texas as long as you follow federal rules and check the state’s Prescription Monitoring Program (PMP) before prescribing.
New York: New York recently finalized regulations aligning state law with federal telehealth allowances. As of mid-2025, you can prescribe controlled substances via telemedicine in New York as long as it’s consistent with DEA waivers. New York does require periodic in-person visits for Medicare patients receiving tele-mental health (once every 6–12 months), but that’s a Medicare billing rule, not a state prescribing ban.
California: California law requires a ‘good faith exam’ before prescribing, but telehealth evaluations count. There’s no state-level prohibition on controlled substance prescribing via video. California defers to federal law on the Ryan Haight Act, so during the DEA waiver period, you can prescribe stimulants and other controlled meds to new patients after a thorough video assessment. You must enroll in California’s CURES (PMP) system and check it before prescribing Schedule II–IV drugs.
If you’re a psychiatrist, you don’t need collaborative agreements or physician oversight in any state. You’re licensed to practice independently, full stop.
But if you’re supervising or collaborating with PMHNPs, the rules get more complicated (more on that below).
Psychiatric Mental Health Nurse Practitioners have varying levels of prescribing authority depending on where they practice. The basic breakdown:
In about 34 states, PMHNPs can practice and prescribe independently without physician oversight. They can:
Examples of FPA states include Washington, Oregon, Arizona, New Mexico, Colorado, Minnesota, and (after meeting experience requirements) New York, Illinois, and California.
In these states, a PMHNP’s prescribing authority is functionally the same as a psychiatrist’s — they just operate under nursing board oversight rather than the medical board.
In ‘reduced practice’ states, PMHNPs need a collaborative practice agreement (CPA) with a physician to prescribe. The physician doesn’t have to be on-site, but the agreement must outline:
New York and Illinois fall into this category with a twist: they require initial collaboration (2 years in NY, 4,000 hours in IL) but then grant independence once the NP meets experience thresholds.
Pennsylvania currently requires collaborative agreements indefinitely — there’s no pathway to independence yet, though legislation has been introduced.
In ‘restricted’ states like Texas and (partially) Florida, PMHNPs must practice under continuous physician supervision. In Texas, this means:
In Florida, PMHNPs are excluded from the state’s ‘autonomous APRN’ category (which only covers primary care NPs). They must work under a supervising physician’s protocol. However, Florida does allow PMHNPs to prescribe psychotropic controlled substances if they have a collaboration agreement with a psychiatrist and meet the state’s definition of a ‘psychiatric nurse’ (MSN/DNP in psych nursing + 2 years of supervised experience).
For most psychiatric services, yes — slightly.
Medicare reimburses NPs at 85% of the physician fee schedule. So if a psychiatrist gets paid $95 for a 15-minute med check (CPT 99213), an NP billing under their own NPI gets about $81.
Private insurers vary. Some pay NPs at parity with physicians (especially in states with equal reimbursement laws like Maryland and Nevada). Others follow Medicare’s 85% rule.
For a solo PMHNP or a telehealth platform, this can add up. If you’re seeing 30 patients a week at $15 less per visit, that’s $450/week in lost revenue compared to a psychiatrist doing the same work.
Let’s talk numbers.
For Medicare patients in 2026, here’s what psychiatrists can expect per visit:
| CPT Code | Service | Medicare Rate (National Avg) |
|---|---|---|
| 90792 | Initial psychiatric eval with med services (60 min) | ~$173 |
| 99213 | Follow-up med check (15 min, moderate complexity) | ~$95 |
| 99214 | Follow-up med check (25 min, high complexity) | ~$136 |
If you’re billing psychotherapy add-on codes (e.g., 20 minutes of therapy + med management), you can stack them:
PMHNPs billing under their own NPI get 85% of these amounts for Medicare patients.
Private insurance typically pays more — often 20–50% above Medicare rates depending on the region and payer. A 99214 might pay $180–$200 in a high-cost-of-living area.
Medicaid pays less, but many state Medicaid programs have increased behavioral health reimbursement in recent years. Florida Medicaid might pay $60–$80 for a brief med check; California Medi-Cal pays about 75% of Medicare rates (though recent investments aim to raise that).
In most cases, yes.
Thanks to pandemic-era reforms that have largely stuck around, Medicare and most private insurers pay the same rate for telehealth psychiatric visits as in-person visits. About 43 states have telehealth parity laws requiring insurers to cover (and in many cases, reimburse equally) services delivered via video.
States with strong parity laws include:
Texas is an outlier — it requires insurers to cover telehealth but doesn’t mandate payment parity. In practice, many insurers pay equally for tele-mental health anyway, given the high demand.
One important exception: audio-only telehealth (phone visits) is now reimbursable for mental health services under Medicare and many state Medicaid programs, as long as the patient cannot access video. This was a pandemic-era fix to address the digital divide, and it’s been extended through at least 2025.
Here’s the reality most providers don’t talk about: acquiring a qualified psychiatric patient costs a lot more than you think.
If you’re trying to build a telehealth practice from scratch through DIY marketing, you’re looking at:
When you factor in all costs — ad spend, staff time to handle and qualify leads, no-show rates from cold leads, failed campaigns, and months of investment before results — acquiring a psychiatric patient through DIY channels typically costs $200–$500+ per patient.
That’s a lot of risk and upfront capital for a provider who just wants to see patients.
Klarity Health uses a pay-per-appointment model similar to Zocdoc, but with a key difference: you’re not gambling on unqualified leads or paying monthly fees whether you see patients or not.
Here’s how it works:
Instead of spending $3,000–$5,000/month on marketing with uncertain ROI, you pay only when a qualified patient books with you. That’s guaranteed ROI instead of gambling on marketing channels.
For providers starting out, scaling, or simply wanting to focus on clinical work instead of business development, it removes the entire patient acquisition risk.
If you’re a psychiatrist, you have maximum flexibility. You can see patients across state lines via telehealth (as long as you hold the appropriate state licenses), prescribe the full range of psychiatric medications, and bill at full physician rates.
If you’re a PMHNP, your ability to practice independently and prescribe depends entirely on where your patients are located. In FPA states or states with experience-based independence (NY, IL, CA), you operate similarly to a psychiatrist after meeting thresholds. In restricted states (TX, FL, PA), you’ll need physician collaboration — which can be a barrier to entry and a cost center.
For both provider types, telehealth has leveled the playing field in terms of access and reimbursement. You can deliver high-quality psychiatric care remotely and get paid fairly for it, as long as you navigate state licensing and prescribing rules correctly.
And if you’re tired of spending time and money on patient acquisition instead of clinical work, platforms like Klarity remove that headache entirely. You focus on medicine; the platform handles the marketing, credentialing, and patient matching.
Prescribing regulations in psychiatry are evolving quickly. The DEA will likely finalize new controlled substance rules by late 2024 or early 2025. States continue to expand PMHNP scope of practice (watch for Pennsylvania and other states to potentially grant FPA in the next legislative session).
The key is to:
If you’re building a telehealth practice or joining a platform, make sure the infrastructure supports compliance: secure video, e-prescribing integrated with state systems, consent workflows, and clear protocols for emergencies.
And if you want to skip the patient acquisition grind and get straight to seeing patients, explore platforms like Klarity Health that handle the hard parts for you.
Ready to join Klarity’s provider network? Learn more about becoming a Klarity provider and start seeing patients without the marketing overhead.
California Board of Registered Nursing – AB 890 Implementation FAQs. Updated November 2023. https://www.rn.ca.gov/practice/ab890.shtml
Texas Board of Nursing – APRN Practice FAQ. Revised 2021. https://www.bon.texas.gov/faqpracticeaprn.asp.html
Florida Statutes Chapter 464 – Nursing Practice Act (Section 464.012 on prescriptive authority and telehealth). 2024 Statute Compilation. https://www.flsenate.gov/laws/statutes/2024/464.012
Nixon Peabody LLP – ‘New York State Finalizes Telemedicine Rule for Controlled Substances.’ June 18, 2025. https://www.nixonpeabody.com/insights/alerts/2025/06/18/new-york-state-finalizes-telemedicine-rule-for-controlled-substances
National Law Review – ‘Telehealth and In-Person Visits: Tracking Federal and State Updates Post-Pandemic Era.’ August 15, 2025. https://natlawreview.com/article/telehealth-and-person-visits-tracking-federal-and-state-updates-pandemic-era
Find the right provider for your needs — select your state to find expert care near you.